This brand name is authorized in Estonia, Japan.
The drug TRILAFON contains one active pharmaceutical ingredient (API):
1
|
UNII
FTA7XXY4EZ - PERPHENAZINE
|
|
Perphenazine is a depressant which blocks dopamine receptors in the central nervous system. It binds to dopamine D1 and D2 receptors and inhibits their activity. Its antiemetic action is mainly due to the inhibition of D2 receptors in the center of the vomiting. Perphenazine also binds to alpha adrenergic receptors and in conjunction with G proteins activate the phosphatidylinositol-calcium system. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| N05AB03 | Perphenazine | N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AB Phenothiazines with piperazine structure |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1598452, 1606159, 1773176 |
| JP | 医薬品医療機器総合機構 | 1172006F1030, 1172006F2045, 1172006F3033, 1172007B1033 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.